The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003.
Nikhil Wagle
Consultant or Advisory Role - Foundation Medicine
Stock Ownership - Foundation Medicine
Nancy U. Lin
No relevant relationships to disclose
Andrea L. Richardson
No relevant relationships to disclose
Ignaty Leshchiner
No relevant relationships to disclose
Ingrid A. Mayer
No relevant relationships to disclose
Andres Forero-Torres
No relevant relationships to disclose
Timothy J. Hobday
No relevant relationships to disclose
Elizabeth Claire Dees
No relevant relationships to disclose
Rita Nanda
No relevant relationships to disclose
Mothaffar F. Rimawi
Research Funding - GlaxoSmithKline
Hao Guo
No relevant relationships to disclose
William Thomas Barry
No relevant relationships to disclose
Antonio C. Wolff
No relevant relationships to disclose
Stacey B. Gabriel
No relevant relationships to disclose
Levi A. Garraway
Consultant or Advisory Role - Foundation Medicine
Stock Ownership - Foundation Medicine
Eric P. Winer
No relevant relationships to disclose
Ian E. Krop
No relevant relationships to disclose